- Home
- COCP vs BLRX Comparison
COCP vs BLRX Comparison
Compare COCP & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COCP | BLRX |
|---|---|---|
| Founded | 2006 | 2003 |
| Country | United States | Israel |
| Employees | 11 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.6M | 12.6M |
| IPO Year | 2011 | 2010 |
Fundamental Metrics
Financial Performance| Metric | COCP | BLRX |
|---|---|---|
| Price | $1.11 | $2.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $6.00 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 41.4K | 8.8K |
| Earning Date | 03-27-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,712,091.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.86 | $2.30 |
| 52 Week High | $2.19 | $7.77 |
Technical Indicators
Market Signals| Indicator | COCP | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 57.22 | 41.80 |
| Support Level | $1.00 | N/A |
| Resistance Level | $1.11 | $3.93 |
| Average True Range (ATR) | 0.05 | 0.16 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 68.73 | 16.31 |
Price Performance
Historical ComparisonAbout COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.